Improving Outcome in Schizophrenia Through Identification of Genetic Risk Factors

Launched by NORTHWESTERN UNIVERSITY · Sep 12, 2005

Keywords

ClinConnect Summary

This clinical trial is focused on understanding how certain genetic factors may influence how well patients with schizophrenia, schizoaffective disorder, bipolar disorder, or major depression respond to a treatment called clozapine, as well as other antipsychotic medications. Researchers want to confirm earlier findings that suggest genetics can help predict which patients will benefit from these treatments.

To participate in the study, individuals aged 65 to 74 and those between 23 and 740 who have been diagnosed with schizophrenia, schizoaffective disorder, bipolar disorder, or major depression with psychotic features may be eligible. Volunteers without a history of any psychotic disorder can also join. Participants will have the opportunity to contribute to important research that could improve treatment for these mental health conditions. It’s important to note that people with different types of psychiatric diagnoses, aside from those mentioned, will not be included in the study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with the diagnoses of schizophrenia or schizoaffective disorder, and bipolar disorder or major depression with psychotic features, or volunteers with no history of a psychotic disorder.
• Exclusion Criteria:
• • Patients with DSM-IV diagnoses other than schizophrenia or schizoaffective disorder, and bipolar disorder or major depression with psychotic features.